Dr. Thomas M. Habermann, MD

Dr. Habermann practices at Mayo Clinic Breast Diagnostic Clinic in Rochester, Minnesota.

Dr. Habermann's NPI, 1790757672, was assigned on February 3, 2006. Dr. Habermann graduated from Creighton University School of Medicine - Omaha in 1979. Dr. Habermann holds Minnesota license 25432.

Dr. Habermann's primary practice is Mayo Clinic Breast Diagnostic Clinic, at 200 First Street SW, Rochester, MN 55905. The practice phone is (507) 284-5968.

Dr. Habermann's primary practice is Mayo Clinic Breast Diagnostic Clinic in Rochester, Minnesota. Dr. Habermann is also affiliated with Mayo Clinic Hospital, Saint Marys Campus. The medical group on file is Mayo Clinic. Dmand AI also links Dr. Habermann to 1 more hospital, 1 clinical lab and 1 hospice, each named with a free account. Dr. Habermann's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Habermann practices, 5 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Habermann's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Habermann is board certified in hematology by the American Board of Internal Medicine. Dr. Habermann is licensed in Minnesota.

Dmand AI lists anemia, chronic anemia, chronic leukemia, immune deficiency disease, lymphoma and neutropenia among the conditions Dr. Habermann treats.

CMS data shows 2,527 Medicare services from Dr. Habermann across 9 procedure codes in 2024, for 283 Medicare patients. Medicare paid $52,926 for them.

CMS counts 283 Medicare patients who saw Dr. Habermann in 2024. The largest group is 65 to 74, with 140 patients. 70% of them have high cholesterol, and 68% have high blood pressure. 4% are also on Medicaid. Their average risk score is 2.03, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Habermann's median patient age at 72, with 41% women.

In 2024, Dr. Habermann wrote 271 Medicare Part D claims for 57 patients. 79% of them were for generic drugs. CMS names the drug for 95 of them, across 6 drugs with 11 or more claims each, at $718,339 in total drug cost. In 2023, CMS named 53 claims across 3 drugs.

Dr. Habermann accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Habermann as offering telehealth.

Dmand AI links 426 papers to Dr. Habermann, published from 2003 to 2025. 2021 was the busiest year, with 32. The most frequent topics are Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols and Rituximab. Dr. Habermann has published most often in Am J Hematol. Dr. Habermann's most frequent co-authors are Thomas E. Witzig, MD, Stephen M. Ansell, MD and Grzegorz S. Nowakowski, MD.

Dmand AI links Dr. Habermann to 6 clinical trials, 2 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Lymphoma, B-Cell, Marginal Zone, Lymphoma, Large B-Cell, Diffuse and Lymphoma, B-Cell. Mayo Clinic sponsors the most, 2.

CMS Open Payments shows 5 general payments to Dr. Habermann from 4 drug and device companies from 2016 to 2024. Honoraria make up the largest share, 75% of the total. Pfizer Inc. paid the most, $12,600. It also lists 2 research payments totaling $995 from 2016 to 2024.

Dmand AI lists 2 awards for Dr. Habermann, most recently America's Top Doctors in 2014.

Dr. Habermann graduated from Creighton University School of Medicine - Omaha in 1979. Dr. Habermann is a member of ASCO.

Dr. Habermann is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.